Thus, pharmacological PXR activation with specific ligands might be beneficial to alleviate symptoms via immunosuppressive effects on lymphocytes in patients with chronic adult AD in which a Th1/IFN-γ predominant immune response is observed (Table 2). The gene discussed is NR1I2; the disease is Alzheimer disease.